background
viral
infect
contribut
morbid
cystic
fibrosi
cf
impact
respiratori
virus
develop
airway
diseas
poorli
understood
method
infant
cf
identifi
newborn
screen
enrol
prior
month
age
particip
prospect
observ
studi
center
clinic
data
collect
clinic
visit
weekli
phone
call
multiplex
pcr
assay
perform
nasopharyng
swab
detect
respiratori
virus
routin
visit
symptomat
particip
underw
bronchoscopi
bronchoalveolar
lavag
bal
subset
underw
pulmonari
function
test
present
find
month
life
result
seventi
infant
enrol
mean
age
month
rhinoviru
preval
viru
follow
parainfluenza
coronaviru
particip
median
viral
posit
swab
rang
past
viral
infect
associ
elev
neutrophil
concentr
bacteri
isol
bal
fluid
includ
recoveri
classic
cf
bacteri
pathogen
antibiot
prescrib
respiratoryrel
indic
virus
identifi
instanc
conclus
earli
viral
infect
associ
greater
neutrophil
inflamm
bacteri
pathogen
earli
viral
infect
appear
contribut
initi
lower
airway
inflamm
infant
cf
antibiot
commonli
prescrib
set
viral
infect
futur
investig
examin
longitudin
relationship
viral
infect
airway
microbiom
antibiot
use
allow
us
elucid
interplay
factor
young
children
cf
cystic
fibrosi
cf
lung
diseas
begin
first
month
life
lower
airway
inflamm
airflow
limit
structur
abnorm
chest
ct
histor
airway
inflamm
attribut
bacteri
infect
though
viral
infect
also
play
import
role
cf
pulmonari
diseas
furthermor
evid
structur
airway
diseas
includ
bronchiectasi
report
infant
cf
even
absenc
bacteri
pathogen
find
suggest
factor
viral
infect
may
initi
inflamm
chronic
infect
progress
lung
diseas
characterist
cf
lung
diseas
infect
respiratori
virus
link
acut
clinic
deterior
children
cf
compar
healthi
counterpart
infant
cf
acquir
viral
infect
similar
frequenc
greater
risk
prolong
sever
lower
respiratori
tract
symptom
persist
lower
airway
obstruct
infant
cf
hospit
viral
infect
greater
pulmonari
inflamm
base
higher
neutrophil
neutrophil
elastas
ne
concentr
bronchoalveolar
lavag
bal
fluid
compar
control
viral
infect
schoolag
children
cf
lead
declin
forc
expiratori
volum
one
second
fev
valu
rhinoviru
infect
specif
risk
factor
failur
recov
fev
follow
pulmonari
exacerb
viral
infect
children
cf
associ
new
acquisit
common
bacteri
pathogen
includ
haemophilu
influenza
streptococcu
pneumonia
moraxella
catarrhali
sever
viral
infect
requir
hospit
link
earli
infect
pseudomona
aeruginosa
antivir
intervent
palivizumab
reduc
rate
length
hospit
due
rsv
infect
cf
infant
howev
shown
differ
age
first
acquisit
p
aeruginosa
aureu
healthi
infant
typic
treat
conserv
observ
support
care
viralinduc
symptom
resolv
howev
manag
decis
infant
cf
may
complex
understand
respiratori
virus
contribut
earli
acquisit
evolut
bacteri
flora
cf
airway
could
lead
modif
immun
strategi
treatment
decis
hypothes
viral
infect
alter
bacteri
flora
inflammatori
profil
airway
contribut
develop
pulmonari
diseas
infant
cf
describ
frequenc
respiratori
viral
infect
infant
cf
explor
potenti
sequela
includ
associ
respiratori
symptom
airway
inflamm
bacteri
colon
pulmonari
function
measur
also
examin
antibiot
prescrib
pattern
set
viral
ill
particip
enrol
four
site
riley
hospit
children
indianapoli
usa
st
loui
children
hospit
st
loui
usa
princess
margaret
hospit
children
perth
australia
royal
children
hospit
melbourn
australia
studi
approv
obtain
regulatori
board
institut
written
inform
consent
obtain
parent
prior
enrol
particip
identifi
newborn
screen
enrol
month
age
inclus
criteria
includ
diagnosi
cf
base
sweat
chlorid
level
meql
two
pathogen
cystic
fibrosi
transmembran
conduct
regul
cftr
variant
exclus
criteria
includ
inabl
success
safe
perform
studi
visit
studi
visit
schedul
interv
coordin
routin
clinic
appoint
histori
physic
examin
perform
visit
parent
contact
weekli
via
telephon
assess
new
respiratori
symptom
use
standard
questionnair
onlin
supplement
nasopharyng
np
swab
obtain
research
clinic
visit
particip
symptomat
parent
collect
nasopharyng
swab
home
floqswab
tm
utm
tm
viral
transport
media
copan
diagnost
murrieta
ca
parent
train
collect
techniqu
research
personnel
clinic
onlin
supplement
viral
analysi
perform
special
project
laboratori
washington
univers
respiratori
viru
polymeras
chain
reaction
pcr
perform
use
genmark
esensor
respiratori
viral
panel
genmark
diagnost
inc
carlsbad
ca
infant
pulmonari
function
test
pft
perform
subset
infant
use
rais
volum
techniqu
coupl
plethysmographi
bronchoscopi
lavag
perform
differ
day
week
apart
per
protocol
bronchoscopi
perform
pulmonari
symptom
time
frame
research
protocol
bal
fluid
collect
follow
inflammatori
mediat
includ
tumor
necrosi
factor
alpha
tnf
analyz
use
commerci
avail
sandwich
enzym
immunoassay
accord
manufactur
recommend
protocol
r
system
minneapoli
mn
function
activ
ne
measur
use
specif
peptid
chromogen
substrat
elastin
product
owensvil
mo
urea
dilut
method
use
determin
cell
count
cytokin
concentr
epitheli
line
fluid
elf
analys
classic
cf
pathogen
defin
haemophilu
influenza
methicillinresist
mrsa
sensit
mssa
staphylococcu
aureu
pseudomona
aeruginosa
stenotrophomona
maltophilia
clinic
treatment
decis
left
discret
treat
physician
studi
data
collect
manag
use
redcap
electron
data
captur
tool
host
indiana
clinic
translat
scienc
institut
analys
perform
evalu
infant
enrol
prospect
longitudin
studi
follow
children
first
year
life
report
establish
cutoff
day
age
includ
avail
physiolog
measur
standard
time
period
track
viral
symptom
data
data
analyz
crosssect
use
longitudin
data
analys
particip
divid
two
group
never
viru
viru
respect
endpoint
infant
pft
bronchoscopi
day
age
infant
height
weight
zscore
gener
use
age
adjust
algorithm
comparison
perform
use
student
test
continu
variabl
logtransform
wilcoxonkruskalw
test
data
skew
chisquar
test
categor
variabl
fisher
exact
test
cell
count
small
gener
linear
model
glm
run
includ
covari
control
possibl
confound
effect
includ
age
site
gener
estim
equat
gee
perform
observ
level
data
account
intraparticip
correl
present
repeat
measur
gee
allow
use
covari
model
run
unadjust
adjust
age
site
age
site
weakli
associ
model
run
one
time
togeth
ensur
collinear
issu
gee
model
also
util
allow
nonnorm
distribut
data
use
perform
continu
binari
endpoint
analys
done
use
sa
sa
institut
cari
nc
p
valu
consid
statist
signific
particip
screen
may
decemb
time
analysi
particip
screen
enrol
includ
analysi
us
australia
fig
onlin
supplement
total
np
swab
test
median
np
swab
per
particip
rang
total
swab
test
differ
countri
p
segreg
particip
base
viral
infect
viru
n
versu
never
viru
n
day
age
outlin
tabl
group
differ
age
race
height
weight
cftr
genotyp
environment
exposur
howev
enrol
viru
group
significantli
male
p
fiftythre
particip
least
one
posit
swab
median
rang
viral
detect
similar
across
studi
site
human
rhinoviru
hrv
frequent
detect
tabl
viral
coinfect
detect
particip
n
viral
posit
significantli
affect
collect
np
swab
research
personnel
versu
parent
median
iqr
rate
record
respiratori
symptom
particip
commonli
report
symptom
cough
nasal
congest
report
encount
cough
nasal
congest
associ
greater
likelihood
viru
detect
ci
ci
respect
tabl
wheez
fever
alter
breath
decreas
activ
level
also
report
significantli
relat
viral
posit
overal
swab
collect
asymptomat
particip
posit
viru
occur
least
n
particip
absenc
symptom
proport
swab
posit
hrv
coronaviru
higher
virus
test
p
overal
infant
receiv
palivizumab
rsv
prophylaxi
age
one
us
howev
differ
rate
rsv
contin
us
vs
au
p
hospit
respiratori
indic
particip
median
age
first
hospit
month
rang
month
hospit
np
swab
collect
within
day
hospit
eleven
posit
respiratori
viru
virus
includ
rhinoviru
n
rsv
n
influenza
n
parainfluenza
n
human
metapneumoviru
n
coinfect
adenoviru
human
metapneumoviru
n
hospit
rate
differ
us
australian
site
never
viru
viru
group
data
shown
bronchoscopi
bal
perform
infant
suffici
data
analys
mean
age
month
particip
viru
group
n
significantli
older
never
viru
group
n
month
month
respect
p
signific
differ
sex
group
time
bronchoscopi
three
infant
pulmonari
symptom
report
time
bal
viru
group
median
time
last
detect
viru
bronchoscopi
day
rang
median
time
last
np
swab
bronchoscopi
day
iqr
day
lavag
absolut
neutrophil
count
higher
particip
previou
viral
infect
vs
cellsml
elf
unadjust
analys
p
adjust
age
time
bal
p
fig
panel
relationship
prior
viru
detect
current
inflammatori
marker
bal
ne
detect
viru
bal
associ
bacteri
growth
never
viru
group
vs
viru
group
p
isol
classic
cf
bacteri
pathogen
bal
fluid
never
viru
group
vs
viru
group
p
tabl
p
aeruginosa
isol
bal
fluid
one
particip
tabl
adjust
analys
account
viral
infect
close
proxim
time
bronchoscopi
within
day
alter
result
data
shown
presenc
classic
pathogen
bal
fluid
turn
associ
greater
pulmonari
inflamm
higher
concentr
ne
p
p
compar
growth
oropharyng
flora
fig
panel
b
onlin
supplement
oropharyng
swab
data
avail
onlin
supplement
fig
tabl
onlin
supplement
administr
prophylact
antistaphylococc
antibiot
earli
infanc
standard
practic
australian
center
australian
particip
treat
amoxicillinclavulan
studi
time
period
three
start
prophylaxi
prior
bal
remain
three
start
shortli
bal
new
antibiot
cours
defin
new
prescript
respiratori
relat
indic
includ
respiratori
symptom
otiti
media
andor
bacteri
erad
first
day
life
infant
us
prescrib
cours
system
antibiot
median
indic
versu
australian
infant
median
p
moreov
american
infant
receiv
antibiot
cours
relat
specif
new
respiratori
symptom
median
australian
infant
median
p
respiratoryrel
indic
us
median
australia
median
p
viral
test
perform
within
day
start
new
antibiot
respiratori
indic
viru
detect
n
n
case
us
australia
respect
p
fig
onlin
supplement
twentyfour
particip
prescrib
new
antibiot
time
bal
adjust
contin
infant
ever
receiv
system
antibiot
irrespect
antistaphylococc
prophylaxi
higher
neutrophil
elastas
p
p
concentr
bal
fluid
nine
infant
classic
cf
pathogen
detect
bal
one
start
antibiot
respons
lavag
find
six
infant
alreadi
antibiot
time
bal
one
pneumonia
three
cough
one
otiti
media
one
result
prior
surveil
oropharyng
cultur
twentyeight
particip
success
complet
infant
pulmonari
function
test
mean
age
month
never
viru
viru
differ
age
p
sex
pulmonari
function
measur
particip
never
viru
vs
viru
group
tabl
onlin
supplement
respiratori
viral
infect
common
infanc
impact
cf
lung
diseas
larg
unknown
studi
viral
infect
associ
increas
airway
inflamm
bacteri
isol
includ
classic
cf
bacteri
pathogen
lower
airway
turn
presenc
classic
cf
pathogen
also
associ
increas
ne
lower
airway
human
rhinoviru
common
viru
detect
isol
frequent
symptom
includ
cough
nasal
congest
case
antibiot
prescrib
respiratoryrel
indic
viru
detect
find
human
rhinoviru
commonli
detect
viru
agre
recent
public
show
high
preval
hrv
earli
life
healthi
children
cf
older
studi
commonli
report
rsv
influenza
adenoviru
youngest
popul
detect
use
immunofluoresc
stain
viru
isol
tissu
respiratori
secret
inde
differ
viral
preval
studi
explain
advent
use
pcr
assay
sensit
diagnost
tool
respiratori
virus
furthermor
studi
sampl
collect
outpati
set
either
clinic
home
eighteen
particip
hospit
respiratori
ill
studi
similar
previou
studi
cf
infant
hospit
viral
infect
rang
show
respiratori
virus
identifi
first
month
life
median
consist
communitybas
birth
cohort
acut
respiratori
ill
infanc
percentag
viral
posit
swab
studi
prior
studi
healthi
infant
show
wide
rang
viral
posit
anywher
compar
studi
examin
virus
first
year
life
found
compar
find
studi
viral
posit
rang
healthi
infant
rate
detect
home
versu
clinic
collect
sampl
significantli
differ
method
parent
collect
success
use
prior
studi
one
studi
perform
emerg
room
show
parent
collect
sampl
equival
physician
collect
sampl
other
demonstr
success
parent
collect
sampl
home
mail
swab
studi
coordin
one
studi
report
mold
mail
sampl
howev
sampl
unlik
maintain
frozen
storag
ship
home
sampl
parent
provid
feasibl
frequent
andor
rapid
sampl
onset
symptom
without
barrier
particip
come
clinic
research
coordin
go
particip
home
unsurprisingli
viral
detect
higher
particip
symptomat
often
cough
nasal
congest
consist
commonli
report
viral
symptom
cf
cohort
increas
lower
respiratori
tract
symptom
report
hrv
infect
especi
infant
underli
lung
diseas
cf
cohort
lower
respiratori
involv
evidenc
wheez
report
exclus
viru
group
howev
infrequ
report
signific
differ
detect
group
find
highlight
import
role
virus
caus
earli
cf
respiratori
symptom
bacteri
pathogen
import
factor
evolut
cf
pulmonari
diseas
earli
surveil
pathogen
lower
airway
infant
cf
link
inflamm
pulmonari
function
declin
found
viral
infect
associ
higher
concentr
lavag
neutrophil
well
presenc
bacteri
isol
includ
classic
cf
pathogen
pathogen
associ
higher
ne
concentr
bal
consist
previou
studi
base
protocol
bronchoscopi
typic
perform
time
clinic
stabil
acut
viral
infect
may
explain
less
signific
inflammatori
respons
detect
viru
group
howev
bacteria
present
lower
airway
clearli
inflammatori
effect
would
expect
particip
found
earli
viral
infect
link
lower
airway
bacteri
isol
increas
incid
classic
cf
bacteri
pathogen
contrast
previou
report
show
chang
colon
infect
typic
cf
pathogen
follow
viral
infect
note
studi
primarili
involv
schoolag
children
underw
bal
detect
virus
obtain
nasopharyng
swab
detect
virus
bal
detect
bacteri
pathogen
may
contribut
differ
find
sever
line
evid
support
mechanist
link
viral
infect
lower
airway
bacteri
colon
viral
infect
damag
epitheli
barrier
thu
facilit
bind
transloc
bacteria
airway
addit
virus
decreas
bacteri
clearanc
contribut
persist
bacteria
within
airway
copd
rhinoviru
specif
shown
impair
bacteri
phagocytosi
macrophag
other
use
vitro
experi
shown
alveolar
macrophag
less
abl
mount
immun
respons
bacteria
follow
hrv
infect
virus
clearli
play
role
airway
signific
may
interact
immun
defens
bacteria
lastli
examin
antibiot
use
young
cohort
infant
cf
contrast
standard
practic
watch
wait
support
care
noncf
infant
viral
infect
choic
use
antibiot
young
children
cf
respiratori
viral
infect
complic
one
hand
consid
antibiot
stewardship
along
potenti
effect
antibiot
commens
organ
develop
microbiom
grow
sensit
among
clinician
regard
use
antibiot
cf
care
symptom
meet
clinic
criteria
pulmonari
exacerb
issu
juxtapos
potenti
benefit
antibiot
treatment
may
individu
exampl
treatment
prevent
concurr
subsequ
bacteri
infect
bacteria
may
link
poorer
longterm
prognosi
data
show
viru
present
roughli
half
instanc
physician
decid
start
new
cours
antibiot
howev
bacteri
cultur
routin
collect
event
therefor
limit
abil
address
potenti
benefit
detriment
treatment
decis
question
particularli
infant
young
children
cf
would
benefit
greatli
investig
studi
sever
limit
first
individu
detect
earli
episod
rsv
hmpv
influenza
limit
abil
specif
investig
effect
individu
viru
rel
small
number
viral
infect
occur
particip
first
month
life
median
therefor
divid
group
never
viru
viru
assum
particip
virus
enrol
never
viru
group
unless
medic
histori
indic
otherwis
possibl
individu
prior
undetect
viral
infect
includ
never
viru
group
physiolog
measur
prior
viral
infect
unabl
assess
whether
children
sever
lung
diseas
like
symptomat
viru
possibl
revers
also
per
studi
design
major
np
swab
collect
infant
symptomat
therefor
could
accur
estim
asymptomat
carrier
rate
infant
complet
bronchoscopi
infant
pft
visit
within
month
enrol
limit
viral
data
avail
prior
visit
short
observ
period
may
influenc
result
subset
particip
abl
complet
pulmonari
function
test
yield
low
number
particip
analysi
small
sampl
size
may
contribut
lack
statist
signific
differ
group
lastli
control
group
due
natur
studi
protocol
includ
bronchoscopi
infant
lung
function
test
sedat
procedur
would
elect
perform
healthi
infant
howev
multipl
epidemiolog
studi
viral
infect
healthi
infant
preval
result
compar
viral
infect
cf
infant
appear
frequent
report
healthi
control
howev
associ
signific
chang
lower
airway
includ
neutrophil
inflamm
greater
frequenc
classic
cf
bacteri
isol
system
antibiot
prescrib
symptomat
particip
half
set
viral
infect
futur
studi
examin
relationship
viral
infect
antibiot
use
airway
microbiom
time
allow
us
better
understand
interact
identifi
appropri
intervent
